Valuentum Exclusive Analysis for the Discerning Investor

Asset Light, Free-Cash-Flow Generating Powerhouse Bookings Holding (Priceline) Remains One of Our Favorite Ideas
Image shown: Booking Holdings' equity has been a strong performer the past few years.Booking Holdings fills an important void in our Best Ideas Newsletter portfolio as it provides exposure to the broader global economy, while albeit cyclical, continues to hold up despite myriad threats. Bookings Holdings’ asset-light business model translates to tremendous free cash flow generation, and its balance sheet is net-cash rich, two considerations that provide a very strong foundation for our estimate of its intrinsic value, which stands at ~$2,150 (shares are trading at ~$1,900 at the time of this writing). The company does not pay a dividend.

Oct 17, 2019

An Update on Facebook’s Libra as Roughly Two Dozen Members Sign On
Image Shown: Facebook has room to run higher, with or without Libra. While several large financial technology and payment processing firms have recently made it clear they no longer want to be a part of the nascent Libra Association, that didn’t stop roughly two dozen members from signing the group’s charter in Geneva, Switzerland, on October 15. We really must stress that our discounted free cash flow models for Facebook don’t take in account the upside its proposed asset-back cryptocurrency Libra might generate. This opportunity represents pure upside to our forecasts, and we continue to like Facebook as a top holding in our Best Ideas Newsletter portfolio.

Sep 24, 2019

The Orthodontics Industry Is Getting Disrupted
Image Source: SmileDirectClub Inc - S-1 SEC Filing. SmileDirectClub, the teledentistry startup that makes 3D-printed clear aligners which are a cheaper alternative to braces (albeit with drawbacks when compared to the traditional braces route), went public this September at $23/share. While SmileDirectClub’s growth trajectory is quite intriguing, we prefer to wait until we get a better idea of the regulatory landscape the start-up faces and what its financial performance will look like now that it’s a public entity in the limelight. For Align, we are staying firmly away from the company as competitive pressures will continue to mount going forward. Neither company pays out a common dividend at this time.

Jul 17, 2019

In the News: Second-Quarter Earnings Season Begins
Second-quarter earnings season is upon us. The markets aren’t expecting much growth. Core industrial names may not fare well, but thus far, big pharma is solid. We’re not making any changes to the newsletter portfolios.

Jun 7, 2019

Exact Sciences: Great Company But Most of the Upside Is Behind It
Image Source: Exact Sciences Corp -- IR Presentation. Exact Sciences operates as a molecular diagnostics company built around its Cologuard offering, which was approved by the US FDA in August 2014. While Exact Sciences stock has performed very well since 2016, the risk-reward trade off isn’t great as things stand today now that shares have zoomed from the single-digits in 2016 to roughly $105 per share as of this writing.

May 8, 2019

Allergan's Peculiar Non-GAAP Reporting, Wendy's Free Cash Flow, More Reports
In alphabetical order by ticker symbol: AGN, EA, ENR, LYFT MYL, PZZA, S, WEN.

Apr 2, 2019

Lyft Takes a Fall, S-1 Reads Like Business School Homework
Image Source: Lyft S-1Reminiscences of the dot-com boom came back to the markets with the over-hyped initial public offering of Lyft, a stock that continues to get shellacked as its first days as a publicly-traded enterprise. Those that know Valuentum know that we wouldn’t touch such investments with a 10-foot pole. The company lost $43 per share in 2018.

Valuentum Exclusive Analysis for the Discerning Investor Symbol Keyword

Member Login

Newsletters/Portfolios

Dividend Cushion

Stock Screens

Products & Tools

Value Trap

The Buying Index, VBI

Dividend Changes

Valuentum Exclusive Analysis for the Discerning Investor